<DOC>
	<DOCNO>NCT01287624</DOCNO>
	<brief_summary>This prospective , multi-center , open-labeled , randomized phase III clinical trial compare overall response rate ( ORR ) , progression free survival ( PFS ) , overall survival ( OS ) toxicity obtain gemcitabine cisplatin combination ( GP ) versus gemcitabine paclitaxel combination ( GT ) .</brief_summary>
	<brief_title>Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel Triple Negative Breast Cancer ( TNBC )</brief_title>
	<detailed_description>The previous phase II study show gemcitabine cisplatin combination ( GP ) effective regimen triple negative breast cancer ( TNBC ) . The potential therapeutic effect GP advance TNBC deserve evaluation yet . Eligible patient randomly assign receive either GP GT regimen verify hypothesis .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Females age 18 70 year old 2 . Histological proven unresectable recurrent advance breast cancer 3 . Triplenegative estrogen receptor ( ER ) , progestogen receptor ( PR ) , human epithelial receptor2 ( HER2 ) immunohistochemistry ( IHC ) test . For patient ER negative , PR negative , Her2 two plus , negative Her2 gene amplification verify FISH test . Her2 one plus may consider FISH verification . 4 . No prior chemotherapy metastatic breast cancer . Prior use taxanes adjuvant/neoadjuvant set acceptable complete 6 month prior enrollment 5 . At least one measurable disease accord response evaluation criterion solid tumor ( RECIST ) 6 . Performance status 1 7 . All patient enrol required adequate hematologic , hepatic , renal function 8 . Life expectancy great 12 week 9 . No serious medical history heart , lung , liver kidney 10 . Provision write informed consent prior study specific procedures 11 . Patients good compliance 1 . Pregnant lactate woman ( female patient childbearing potential must negative serum pregnancy test within 14 day first day drug dosing , , positive , pregnancy rule ultrasound ) 2 . Women childbearing potential , unwilling use adequate contraceptive protection course study 3 . Treatment radiotherapy axial skeleton within 4 week first treatment recovered toxicity previously administer radiotherapy 4 . Treatment investigational product within 4 week first treatment 5 . Symptomatic central nervous system metastasis , except patient stable asymptomatic brain metastasis complete course cranial irradiation , least one measurable lesion outside brain . Radiotherapy complete within 4 week prior registration 6 . Other active malignancy ( include hematologic malignancy ) malignancy within last 5 year , except cure nonmelanoma skin cancer cervical intraepithelial neoplasia . 7 . Patient history clinically significant cardiovascular , hepatic , respiratory renal disease , clinically significant hematological endocrinal abnormality , clinically significant neurological psychiatric condition 8 . Uncontrolled serious infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>triple negative breast cancer</keyword>
	<keyword>fine line chemotherapy</keyword>
</DOC>